Disease · MONDO_0005451
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SPD489 vs PLACEBO: serious adverse events | 3 of 192 | 2 of 187 | 379 | NCT01718483 | Trial comparisons |
| SPD489 vs PLACEBO: serious adverse events | 1 of 181 | 2 of 185 | 366 | NCT01718509 | Trial comparisons |
| Testosterone vs Placebo: deaths from any cause | 0 of 43 | 0 of 47 | 90 | NCT01121211 | Trial comparisons |
| Testosterone vs Placebo: serious adverse events | 4 of 43 | 1 of 47 | 90 | NCT01121211 | Trial comparisons |
| NB Medication vs Placebo: deaths from any cause | 0 of 43 | 0 of 46 | 89 | NCT03539900 | Trial comparisons |
| NB Medication vs Placebo: serious adverse events | 0 of 43 | 0 of 46 | 89 | NCT03539900 | Trial comparisons |
| Vortioxetine vs Placebo: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT02528409 | Trial comparisons |
| Vortioxetine vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT02528409 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: deaths from any cause | 0 of 32 | 0 of 29 | 61 | NCT03926052 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: serious adverse events | 0 of 32 | 0 of 29 | 61 | NCT03926052 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: Binge-Eating Relapse | 3 of 30 | 5 of 28 | 58 | NCT03926052 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: Binge-Eating Relapse | 6 of 20 | 6 of 23 | 43 | NCT03926052 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: Binge-Eating Relapse | 3 of 18 | 2 of 23 | 41 | NCT03926052 | Trial comparisons |
| Topiramate vs Placebo: deaths from any cause | 0 of 16 | 0 of 18 | 34 | NCT00606411 | Trial comparisons |
| Topiramate vs Placebo: serious adverse events | 0 of 16 | 0 of 18 | 34 | NCT00606411 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005451/comparisons